Explore the vast range of titles available.

PurposePseudoprogression is often indistinguishable from true tumor progression on conventional 2-dimensional (2D) MRI in glioblastoma multiforme (GBM) patients. The aim of this study was to determine the association between post-gadolinium 3-dimensional (3D) characteristics and clinical state in GBM patients.MethodsStandardized 3D brain MRI studies were performed, and contrast enhancing portions of each tumor were segmented and analyzed, blinded to clinical state, using principal component analysis (PCA), medial axis transformation (MAT), and coverage analysis. Associations between the 3D characteristics of the post-gadolinium enhanced regions and the clinical status of patients were performed.ResultsA total of 15 GBM patients [male: 11 (73%); median age (range): 62 years (36–72)] with a median disease duration of 6 months (range 2–24 months) were studied cross-sectionally with 6 (40%) patients identified with tumor progression. Post-gadolinium features corresponding to the group with progressive disease exhibited a more spherical and symmetric shape relative to their stable counterparts (p = 0.005). The predictive value of a more uniformly full post-gadolinium enhanced shell to clinical progression was determined with a sensitivity of 66.7% (95% CI 29.9–92.5), specificity of 100% (54.1–100), and PPV of 100% (p = 0.028, 2-tailed Fisher’s exact test). There did not appear to be an association between the thickness of the contrast enhanced shell to clinical state.ConclusionsThe application of 3D technology with post-gadolinium imaging data may inform healthcare providers with new insights into disease states based on spatial, surface, and structural patterns.

The COVID-19 pandemic has underscored the critical need for virus detection methods that are precise, simple, quick, and cost-effective. Electrochemical immunoassay-based methods are a practical solution given their ability to quickly, inexpensively, sensitively, and selectively detect the virus at the point of care. This study details the immunomagnetic capture of SARS-CoV-2 nucleocapsid protein in nasal samples, followed by electrochemical detection using gold nanoparticle labels on a screen-printed carbon electrode. We determined ideal conditions for the size of the gold nanoparticles and the length of the deposition time to maximize the electrochemical signal. The limit of detection for nucleocapsid protein was determined to be 2.64 ng/mL in PBS. The assay was successfully demonstrated to detect nucleocapsid protein in SARS-CoV-2-positive samples with a viral load as low as Ct = 25 (p-value < 0.0001 vs. negative patient control).

One of the two common hallmark lesions of Alzheimer’s disease (AD) brains is neurofibrillary tangles (NFTs), which are composed of hyperphosphorylated tau protein (p-tau). NFTs are also a defining feature of other neurodegenerative disorders and have recently been identified in the brains of patients suffering from chronic traumatic encephalopathy (CTE). However, NFTs are not normally observed in traumatic brain injury (TBI) until months or years after injury. This raises the question of whether NFTs are a cause or a consequence of long-term neurodegeneration following TBI. Two conformations of phosphorylated tau, cis p-tau and trans p-tau, which are regulated by the peptidyl-prolyl isomerase Pin1, have been previously identified. By generating a polyclonal and monoclonal antibody (Ab) pair capable of distinguishing between cis and trans isoforms of p-tau ( cis p-tau and trans p-tau, respectively), cis p-tau was identified as a precursor of tau pathology and an early driver of neurodegeneration in AD, TBI and CTE. Histological studies shows the appearance of robust cis p-tau in the early stages of human mild cognitive impairment (MCI), AD and CTE brains, as well as after sport- and military-related TBI. Notably, cis p-tau appears within hours after closed head injury and long before other known pathogenic p-tau conformations including oligomers, pre-fibrillary tangles and NFTs. Importantly, cis p-tau monoclonal antibody treatment not only eliminates cis p-tau induction and tau pathology, but also restores many neuropathological and functional outcome in TBI mouse models. Thus, cis p-tau is an early driver of tau pathology in TBI and CTE and detection of cis p-tau in human bodily fluids could potentially provide new diagnostic and prognostic tools. Furthermore, humanization of the cis p-tau antibody could ultimately be developed as a new treatment for AD, TBI and CTE.

According to www.ulifeline.org, a website with mental health resources for college students, between 80-90 percent of those who are treated for depression experience significant improvement and almost all individuals gain some relief from their symptoms, whether treatment be through counseling, medication or both.\\n

[...]I dress up for the cult performances; most of the timethe audience dresses in some sort of lingerie or basically any outfit that is appropriateon Halloween but not appropriate for the rest of the year.